ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Epithelial Carcinoma

Triple Negative Breast Cancer trials near Berlin, BE, DEU:

Locations recently updated

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...

Begins enrollment in 2 months
Breast Neoplasms
Drug: Paclitaxel
Drug: Iza-bren

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 217 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Berlin, Germany and 199 other locations

(NACT) is standard of care in all node-positive and in node-negative patients with a tumour size \>5 mm according to current National Compre...

Enrolling
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab govitecan

Phase 2

West German Study Group

Berlin, Brandenburg, Germany and 32 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Berlin, Germany and 516 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Berlin, Germany and 505 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Berlin, Germany and 192 other locations

to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...

Enrolling
Triple-Negative Breast Cancer
Biological: Pembrolizumab
Biological: Sacituzumab tirumotecan

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Berlin, Germany and 209 other locations

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...

Enrolling
Ovarian Neoplasms
Gastric Cancer
Drug: pembrolizumab
Drug: PF-08046054

Phase 1

Seagen
Seagen

Berlin, Germany and 40 other locations

works to treat solid tumor cancers.* Part D will find out if and how much Felmetatug Vedotin can be given with pembrolizumab.* Par ...

Active, not recruiting
Ovarian Neoplasms
Hormone Receptor Positive Breast Neoplasms
Drug: Pembrolizumab
Drug: Felmetatug Vedotin

Phase 1

Seagen, a wholly owned subsidiary of Pfizer

Berlin, Germany and 30 other locations

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer...

Active, not recruiting
Triple Negative Breast Cancer
HER2-negative Breast Cancer
Drug: Sacituzumab govitecan
Drug: Cisplatin

Phase 3

GBG Forschungs GmbH

Berlin, Germany and 162 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems